Sterna Biologicals & KG

Sterna Biologicals is a German biotech focused on disrupting the treatment of type 2 chronic inflammatory diseases through its proprietary GATA-3 targeting platform. The company's lead asset, hgd40, has completed multiple Phase IIa clinical trials in topical formulations for conditions like asthma, atopic dermatitis, ulcerative colitis, and COPD. Sterna operates as a private, clinical-stage company and is actively seeking partnerships to advance its innovative DNAzyme technology. Its approach aims to address the significant unmet need for safer and more efficacious anti-inflammatory therapies beyond corticosteroids and biologics.

DNAzyme-based platform targeting the master transcription factor GATA-3 to downregulate multiple pathways in type 2 chronic inflammation.

Sterna competes in the crowded chronic inflammatory disease space against entrenched corticosteroids, a wide array of biologic drugs targeting specific cytokines (e.g., IL-4, IL-5, IL-13, TNFα), and emerging small molecules. Its differentiation lies in its upstream GATA-3 target and unique DNAzyme modality.